Navigation Links
SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center

MOUNTAIN VIEW, Calif., Sept. 20, 2011 /PRNewswire/ -- SanBio, Inc., a leader in cell therapies for regenerative medicine, has announced the site initiation and opening of a Phase 1/2a clinical trial testing a novel cell therapy product, SB623, in patients suffering from disability resulting from ischemic stroke. The study is taking place at the University of Pittsburgh Medical Center. An additional study site is also open and recruiting patients at the Stanford University Medical Center in Palo Alto, CA.

SB623 has been shown to improve neurological behavior in preclinical models of stroke. In this study, safety and efficacy parameters will be evaluated, including improvements in motor function and cognitive status. The trial will evaluate 18 patients who have suffered an ischemic stroke within the past six to 24 months and have a motor neurological deficit.

"We are excited to be a part of this important new study offering a novel approach to therapy for patients suffering from ischemic stroke disability," said Douglas Kondziolka, MD, Peter J. Jannetta professor and vice chairman of neurological surgery at the University of Pittsburgh Medical Center (UPMC), and Principal Investigator of the study.

"Preclinical models have shown that SB623 restores function in animal models of stroke. With over seven million stroke victims in the U.S. today, we are eager to explore the potential of SB623 in patients who may otherwise be permanently disabled," said Lawrence Wechsler, MD, chair, department of neurology at UPMC.

"With two trial sites now open, our goal is to explore the potential of SB623 as a potential treatment for stroke disability as rapidly as possible," said Keita Mori, Co-CEO of SanBio. "SB623 represents a significant step forward in the development of regenerative therapies."

For more information on the SB623 trial, please visit

About SB623
SB623 is a proprietary regenerative cell therapy consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors. SB623 functions by producing proteins that aid the healing process.

About SanBio
SanBio is a leader in the discovery and development of new regenerative cell therapy products. The company's first product, SB623, is currently in a Phase 1/2a clinical trial for stable stroke patients. In addition to SB623, SanBio is using its proprietary technology to develop programs in Parkinson's disease, spinal cord injury and traumatic brain injury. For more information, please visit

SOURCE SanBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery
2. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
3. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Anesiva Announces Second Quarter 2008 Financial Results and Update
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
9. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
(Date:10/13/2015)... 2015  Cepheid (Nasdaq: CPHD ) today announced ... --> --> Based ... third quarter of 2015 is expected to be approximately ... to be approximately $(0.32) for the third quarter.  Based ... share for the third quarter of 2015 is expected ...
(Date:10/13/2015)... Applied BioMath ( ), a computational ... the drug invention process, announced that it will sponsor ... 20-22, 2015 in Boston , MA.  ... CEO of Applied BioMath, will present "QSP approaches enabling quantitative ... trials" on Wednesday October 21st 2015 at 12:30PM.  ...
(Date:10/13/2015)... YORK , October 13, 2015 ... acceleration and development company, has entered into a strategic ... York and Paris, France ... --> --> This collaborative arrangement ... highly respected scientific advisory team as well as long ...
(Date:10/13/2015)... ... ... Clinovo recently appointed Jeff Parr and Ed Donaldson to its Business Development ... , Jeff Parr has spent the past decade providing quality management software and consulting ... Ab Sciex to name a few. He is based in Salt Lake City, ...
Breaking Biology Technology:
(Date:10/6/2015)... , Oct. 6, 2015  Maverix Biomics, Inc., ... enhancements to its software portfolio with the debut ... for differential expression in eukaryotes. The software is ... a cloud-based genomic analysis solution that leverages proven ... from next-generation sequencing efforts. Garry Nolan,s ...
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 Americans ... of new SCIs estimated to reach 12,500 annually, the ... California Resource Services for Independent Living (SCRS-IL) is ... California opening doors to independence ... programs and services, notably assistive technology services and education. ...
(Date:9/29/2015)... 2015  iDAvatars is excited to be named one of ... market. The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a ... Watson. "It is both an honor and a ... bring to market the cognitive power of IBM Watson in ...
Breaking Biology News(10 mins):